Exploring HLA in tumors: Introduction to HLA in healthy tissue and the tumor microenvironment

Published on May 28, 2026

HLA plays an important role in the immune system and is more and more leveraged in HLA-restricted precision medicine therapies, […]

Read more

NGS vs Sanger-based HLA typing for Companion Diagnostics: key differences and clinical implications

Published on April 23, 2026

While still emerging in clinical practice, HLA-restricted therapies are gaining traction in clinical research and early-stage precision medicine applications (see […]

Read more

The role of HLA in immunotherapy development

Published on March 26, 2026

Human Leukocyte Antigen (HLA) proteins have long been central in the transplantation field, because of their critical role on transplant […]

Read more

GenDx and Treos Bio Announce Partnership to develop HLA-based Companion Diagnostic for PolyPEPI1018 Cancer Immunotherapy

Published on March 17, 2026

PRESS RELEASE Utrecht and London, 17 March 2026 GenDx, a Eurobio Scientific Company, based in the Netherlands, specialized in molecular […]

Read more

Navigating Grey Zones & Growing Pains: Developments in the Regulatory CDx Space

Published on March 16, 2026

About The tremendous advances in the Precision Medicine field are shifting the focus of treatment towards more precise and targeted […]

Read more

Supporting Precision Medicine: Our Companion Diagnostics (CDx) services

Published on February 19, 2026

We are excited to share that GenDx updated its website to better showcase our comprehensive Companion Diagnostics (CDx) services. Our […]

Read more

HLA Typing and Precision Medicine for Oncology Immunotherapy: A New Frontier

Published on November 11, 2025

About From the clinician’s perspective, oncology has undergone a major development in recent years. As cancer research progressed, it became […]

Read more

Lessons learned from a CDx study; A perspective from Regulatory and IVD

Published on November 13, 2024

About During this webinar GenDx and ARC take you along in their recent experiences with a companion diagnostic (CDx), clinical […]

Read more

The ARTEMIA trial – Targeting Non-Small Cell Lung Cancer (NSCLC) with a Therapeutic Cancer Vaccine OSE2101

Published on September 25, 2024

About During this webinar Silvia Comis, MD, head of Clinical Development at OSE Immunotherapeutics presents OSE2101(also known as Tedopi®)  and […]

Read more

GenDx Announces a Collaboration Agreement with OSE Immunotherapeutics

Published on November 21, 2023

PRESS RELEASE Utrecht, 21 November 2023 During the opening of their new offices GenDx Announces a Collaboration Agreement with OSE […]

Read more